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ABSTRACT
Zebrafish are a unique model for pharmacological ma-
nipulation of physiological processes such as inflamma-
tion; they are small and permeable to many small mo-
lecular compounds, and being transparent, they permit
the visualization and quantitation of the inflammatory
response by observation of transgenically labeled in-
flammatory cell populations. Using a transgenic line
specifically labeling neutrophils in vivo (mpx:GFP), we
studied the effects of a range of pharmacological
agents on the resolution of inflammation in vivo. These
agents were selected for their ability to modulate neu-
trophil function and lifespan in human neutrophils in
vitro. Agents delaying neutrophil apoptosis (LPS,
dbcAMP, and several caspase inhibitors) all lead to a
delay in resolution of neutrophilic inflammation. Recip-
rocally, pyocyanin and roscovitine (inducers of neu-
trophil apoptosis) lead to reduced neutrophil num-
bers. The occurrence of apoptosis was observed by
time-lapse analysis and confirmed by dual staining for
neutrophil-specific mpx activity (TSA staining) and an
apoptotic marker (TUNEL). During inflammation, mac-
rophages follow neutrophils into the inflamed site,
and TUNEL/TSA dual-positive material can be demon-
strated within macrophages, consistent with their up-
take of apoptotic neutrophils. This model has several
advantages over mammalian models and lends itself
to the study of pharmaceutical agents modulating
inflammation. J. Leukoc. Biol. 87: 203–212; 2010.
Introduction
Neutrophilic inflammation is a necessary part of the host re-
sponse against infectious disease. However, neutrophil products
are implicated in the tissue damage seen in a range of inflamma-
tory diseases, in a range of organs, including the lung [1]. A ther-
apeutic agent for the removal of neutrophils would be a potential
strategy by which inflammatory disease could be treated, and in-
deed, a precedent for this exists in studies of the CDK inhibitor,
roscovitine [2]. One approach to the identification of such an
agent is to screen compound libraries for entities with the ability
to modulate the inflammatory response. Inflammation is a com-
posite process resulting from dynamic changes in diverse cellular,
molecular, and physiological parameters and as such, cannot be
modeled adequately in vitro. There is, therefore, a need to iden-
tify an in vivo model, in which pharmacological manipulation of
neutrophilic inflammation can be readily assessed.
Zebrafish are a vertebrate model organism, which are becom-
ing widely used for the study of the vertebrate immune system [3,
4]. They possess an immune system with many parallels to mam-
malian systems, including the presence of cells with characteris-
tics of mammalian macrophages, eosinophils, and neutrophils
[5–7], and they have been used to study vertebrate inflammation
(recently reviewed in ref. [8]).
Using a transgenic zebrafish model of spontaneously resolving
tissue neutrophilia [9], we have established a system that permits
in vivo tracking of neutrophil fate in real-time. Using bacterial
artificial chromosome transgenesis, we have generated a mpx:
GFP transgene, which specifically marks zebrafish neutrophils
[9]. The myeloid-specific peroxidase (mpx) gene is the closest
zebrafish (Danio rerio) homologue of the mammalian mpo gene
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(mpo) [6]. Tail injury by scalpel transection under Tricaine anes-
thesia leads to recruitment of fluorescent neutrophils, followed
by spontaneous resolution of this tissue neutrophilia over the
course of 24–48 h, comparable with mammalian models of neu-
trophilic inflammation [10]. Using this model, we have tested a
range of compounds for their ability to modulate the outcome of
the inflammatory process. Compounds modulating human neu-
trophil lifespan in vivo were assessed for their ability to modulate
inflammation resolution in this model. Compounds tested were
caspase inhibitors with differing specificities for a range of
caspases, bacterial LPS, and dbcAMP (a stable synthetic cAMP
analog). Compounds delaying human neutrophil apoptosis were
shown to delay inflammation resolution, and those accelerating
neutrophil apoptosis were found to accelerate inflammation reso-
lution. It has proved difficult previously to identify apoptotic neu-
trophils in the zebrafish model. We show here the identification
of apoptotic neutrophils during inflammation resolution and sug-
gest that this process is functionally important in the resolution
of inflammation in this model.
MATERIALS AND METHODS
Zebrafish and other reagents
Wild-type (AB strain) or transgenic Tg(mpx::eGFP)i114 zebrafish [9] were
maintained according to standard protocols [11]. Reagents were from Sigma
(Poole, UK) unless specified otherwise. Rhodamine TUNEL kit
(ApopTag Red) was from Chemicon (Temecula, CA, USA). Rabbit anti-GFP
antibody was from Torrey Pines Biolabs (La Jolla, CA, USA), and the poly-
clonal rabbit anti-zebrafish L-plastin was a kind gift of Paul Martin (University
of Bristol, UK). Caspase inhibitor zVD.fmk and zVAD.fmk were from Bachem
(Weil am Rhein, Germany).
Compound treatment of zebrafish larvae
Compounds indicated were made up according to the manufacturer’s instruc-
tions in DMSO, such that the final concentration of DMSO was 1% or less.
Appropriate controls of this level of DMSO were included for all experiments.
Compound administration was by immersion of the larvae in a solution of the
test compound diluted in E3 [11]. For assessment of compound activity in
speeding resolution of inflammation, larvae were injured at 3 dpf and recov-
ered. At 4 hours post injury, larvae with a good inflammatory response were
arrayed in the test compound in 96-well plates at three fish/well. For practical
reasons, plates were incubated at 20°C for 20 h (approximately equivalent to
12 h at 18°C) and then scored by examination under fluorescence stereomi-
croscopy.
Assessment of neutrophil number
Anesthetized Tg(MPO::eGFP)i114 larvae were subjected to complete transec-
tion of the tailfin using a microdissection scalpel as described previously
[9] and recovered for the time interval indicated. The larvae were then
re-anesthetized and viewed using a dissecting microscope at 40–100 mag-
nification using a GFP filter set. The number of fluorescent neutrophils at
the site of inflammation was counted by eye.
Fluorescein-TSA staining
Larvae fixed in ice-cold 4% PFA were washed in E2 [11] and incubated at
28°C for 10 min in the dark in a 1:50 dilution of fluorescein- or Cy3-tyra-
mide in amplification diluent (TSAplus kit, Fluorescence Systems, Perkin
Elmer Inc., Waltham, MA, USA). This was followed by 3  10 min washes
in E2 and room temperature fixation in 4% PFA for 30 min.
ApopTag Red in situ apoptosis detection staining
Following TSA staining, as described above, samples were washed for 3  5
min in PBS before the samples were left at room temperature in 10 g/ml
proteinase K for 90 min. The samples were then washed and stained using
the ApopTag Red in situ apoptosis detection kit (Chemicon). The samples
were stored in 75% glycerol at –20°C.
Immunofluorescence
For GFP immunofluorescence following TSA staining as above, samples
were washed in PBS for 3  5 min before incubation with rabbit anti-GFP
(1:1000) overnight at 4°C. Secondary incubation was performed using a
sheep anti-rabbit Alexa488 secondary at 1:500 for 2 h at room temperature.
Staining for L-plastin immunofluorescence was performed according to
the published protocol [12], substituting a sheep anti-rabbit Alexa488 sec-
ondary at 1:500 (Torrey Pines Biolabs).
Neutral red staining
Zebrafish larvae were immersed in a 2.5-g/ml neutral red solution in E2
[5] for 2–4 h [13]. The number of positive cells at the site of injury was
counted using an inverted Nikon TE2000 microscope, and a 20 extra
long working distance objective. A minimum of five larvae for each data
point was assessed.
Image acquisition and processing
Zebrafish larvae were anesthetized by the addition of 0.017% Tricaine to
the E3 medium, in which they were maintained [11]. GFP was visualized by
excitation at 488 nm. No nonlinear normalization of images was per-
formed. Images were acquired at 20–22°C using an FV1000 Olympus con-
focal microscope (mounted on a BX61, driven by FV10-ASWv1.4 software)
or a Perkin-Elmer UltraVIEW VoX spinning disk confocal microscope
mounted on a Zeiss Axiovert 200M, driven by Volocity 4.3 software (Perkin
Elmer Inc.). Excitation was with the 488 and 543 laser lines.
Statistical analysis
Data were analyzed (Prism 5.0, GraphPad Software, San Diego, CA, USA)
using unpaired, two-tailed t-tests for comparisons between two groups and
one-way ANOVA (with appropriate post-test adjustment) for other data.
Ethical approvals
These studies have been subjected to appropriate local ethical review and
were performed in accordance with UK Home Office legislation. UK law
requires that where possible, experiments are performed on animals not
protected under the Animals (Scientific Procedures) Act. Therefore, where
possible, experiments were performed on unprotected embryos, 5.2 dpf.
Older embryos were used where necessary for identification of apoptotic
neutrophils, as numbers of neutrophils were higher at this age.
RESULTS
Pharmacological modulation of inflammation
resolution in vivo
Previous work in human neutrophils has identified a range of
compounds that modulate neutrophil lifespan. Earlier experi-
ments in the zebrafish model had suggested to us that caspase
inhibition with a dipeptide pan-caspase inhibitor zVD.fmk [9]
was able to delay inflammation resolution. However, whether
this relates to altered cytokine processing or altered neutrophil
apoptosis is not clear. To explore this phenomenon further, a
range of inhibitors of neutrophil apoptosis was tested for their
ability to modulate the resolution of inflammation. The aspect
of inflammatory process most pertinent to these studies is the
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number of neutrophils representing the cellular component of
inflammation and is assessed by counting of infiltrating inflam-
matory cells, marked by the transgene GFP. Previous experi-
ments have defined the time course of inflammation, and 6 h
post-injury represents the peak inflammation, and 24 h repre-
sents a time-point at which inflammation has largely resolved
in untreated larvae. Counting the number of inflammatory
neutrophils at two time-points in the same larva permits an
analysis of the change in neutrophil number over time in indi-
vidual animals. This is particularly useful when looking for dif-
ferences not apparent in pooled batches of wild-type fish,
which can only be examined at a single time-point. In control
animals, between 6 h and 24 h after injury, the mean (sem)
reduction in neutrophil numbers is 48.1  7.9% [9]. The
most potent caspase inhibitor tested (zVD.fmk, a dipeptide
inhibitor of all caspases) reduces this figure to 0.5  8.1%
(Fig. 1A, shown for comparison) [9]. A caspase inhibitor with
increased specificity for caspases-3, zDEVD.fmk has the next-
largest effect on inflammation resolution (Fig. 1B), which
might be expected as a result of the downstream effector
nature of this caspase. An inhibitor with increased specific-
ity for caspase-9 also delayed resolution (Fig. 1C). Inhibitors
with increased specificity for caspase-8, zIETD.fmk did not
show a statistically significant difference in these experi-
ments. This might support a role for mitochondrial path-
ways of apoptosis in inflammation resolution in this model,
and this would be supported by existing data from human
neutrophils [14, 15].
Two other agents predicted to delay neutrophil apoptosis
in vivo also affect inflammation resolution: bacterial LPS
[16 –18] and dbcAMP [19] (Fig. 1, E and F). These data
suggest that this model is suitable for identifying agents that
delay inflammation resolution and further support the hy-
pothesis that neutrophil apoptosis is functionally important
in this process.
For the identification of potential therapeutics, however, it is
important to test whether the reciprocal situation is also true:
whether we can assay for the acceleration of inflammation res-
olution by removal of inflammatory neutrophils. In vitro
agents shown to accelerate neutrophil apoptosis include pyocy-
anin and roscovitine. Pyocyanin is a phenazine pigment exo-
toxin of Pseudomonas aeruginosa, which is a profound inducer
of neutrophil apoptosis in human and mouse models [20, 21].
To test the effects of this agent in the transgenic model of in-
flammation resolution, we tested pyocyanin initially for its abil-
ity to reduce the number of neutrophils recruited to a site of
tissue injury. Figure 2A shows neutrophil numbers at a single
time-point during the initiation phase of inflammation; hence,
absolute neutrophil numbers are shown. The number of neu-
trophils present at the site of inflammation was reduced by
pyocyanin treatment, reflecting a blockade of recruitment or
an induction of neutrophil apoptosis. The effect of pyocyanin
on neutrophil number was reversed by the addition of
zVD.fmk, confirming pyocyanin induces caspase-dependent
cell death in this experimental paradigm [22]. Although neu-
trophil apoptosis induction might be expected to reduce neu-
trophil numbers, if this were a result of an unphysiological loss
of neutrophils, and clearance were overwhelmed, secondary
necrosis would ensue, causing more tissue damage and in-
creased inflammatory cell recruitment. To exclude this possi-
bility, we repeated these experiments to assess the effect of
apoptosis induction during prolonged exposure during the
resolution phases of inflammation. For these experiments, in-
flammation was initiated as before and was allowed to progress
for 4 h. At that time, larvae with robust inflammatory re-
sponses were selected and incubated with media alone, DMSO,
pyocyanin, or roscovitine. After a further period in control
and DMSO-treated larvae, there were significant numbers of
neutrophils persisting at the inflammatory site. Pyocyanin was
added at 4 h post-injury at a time when inflammation is estab-
lished, and the effects on inflammation resolution were as-
sessed at a time when inflammation is resolving, although
there are still a significant number of persisting neutrophils in
untreated larvae. There were fewer persisting neutrophils in
the pyocyanin-treated group, suggesting that pyocyanin has
accelerated the resolution of inflammation (Fig. 2B).
Roscovitine, an inhibitor of CDKs, has been shown to be an
inducer of neutrophil apoptosis and in addition, is able to in-
duce inflammation resolution in a variety of murine models of
inflammation [2]. We therefore tested roscovitine alongside
pyocyanin for its ability to induce resolution of inflammation.
The number of persisting neutrophils was reduced following
roscovitine treatment to a level comparable with that seen with
pyocyanin treatment.
A preliminary compound screen to identify
compounds accelerating inflammation resolution
The ability to reduce the number of inflammatory cells at a site
of tissue injury, as can be seen with pyocyanin and roscovitine in
this model, is a potential therapeutic strategy for the treatment of
inflammatory disease. We therefore sought to show the potential
use of this model for drug discovery, by performing a prelimi-
nary, proof-of-principle compound screen to identify compounds
accelerating inflammation resolution. The experimental design
was as described above, except that for convenience larvae were
incubated at 18°C overnight to lengthen the time to reach a suit-
able end point. From a 960 compound subset of the spectrum
collection (MicroSource Discovery, Gaylordsville, CT, USA), we
identified 12 compounds with activity in this assay. Of these, six
were known to possess anti-inflammatory activity. Of these, flu-
methasone (a corticosteroid in use in veterinary practice) is the
best-characterized and exhibits a convincing dose-response rela-
tionship (Fig. 2C). The effects of corticosteroids in the zebrafish
inflammation model have been reported previously [23], con-
firming the validity of this unbiased method for the identification
of anti-inflammatory compounds. Flumethasone suppresses num-
bers of neutrophils at the site of injury below levels seen with pyo-
cyanin, the positive control compound. This confirms the ability
of this model to identify anti-inflammatory compounds, and it
would be expected that novel compounds might be identified
through a similar screen of novel compounds.
Visualization of apoptotic morphology in neutrophils
in vivo
Studies by other research groups have failed to identify
apoptotic neutrophils in zebrafish inflammation [24, 25]. As
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the data presented here suggest that neutrophil apoptosis may
be functionally important in inflammation resolution, we
sought supporting evidence for neutrophil apoptosis in the
resolution phase of neutrophilic inflammation.
Following tail transection in mpx:GFP zebrafish and using
spinning disk confocal microscopy, we identified neutrophils
participating in the inflammatory response. Among these, neu-
trophils were seen that exhibited morphological features typi-
Figure 1. Pharmacological delay
of neutrophil apoptosis is associ-
ated with a defect in resolution
of the cellular component of the
inflammatory response following
tissue injury in the zebrafish.
(A–F) Three dpf mpx:GFP ze-
brafish were injured by tailfin
transaction, as described previ-
ously [9]. Counts of fluorescent
neutrophils at the site of injury
were made at 6 h and 24 h after
injury. For each fish, the percent
reduction in neutrophil numbers
between these time-points was
calculated. This is a measure of
the percentage resolution of the
neutrophilic component of the
inflammatory response. Each data
point corresponds to counts from
a single fish. The compounds in
question or a comparable vehicle
control were added at 4 h after
injury. (A) zVD.fmk 100 M
(pan-caspase inhibitor, Calbio-
chem, UK); (B) zDEVD.fmk 100
M (caspase-3 inhibitor, Bachem,
Germany); (C) benzyloxycar-
bonyl-Leu-Glu-His-Asp-fluoro-
methylketone (zLEHD.fmk), 100
M (caspase-9 inhibitor, Calbio-
chem); (D) zIETD.fmk 100 M
(caspase-8 inhibitor, Calbio-
chem); (E) highly purified bacte-
rial LPS 1 M (Alexis Pharma-
ceuticals, San Diego, CA, USA);
(F) dbcAMP 100 M (Sigma).
P values were generated by two-
tailed unpaired Student’s t-test.
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cal of apoptosis, namely, loss of locomotion and loss of pseu-
dopod formation and rounding (Fig. 3 and Supplemental
Movies 1 and 2). At an interval after the assumption of a
rounded shape (66 min in this example), there is an abrupt
loss of GFP fluorescence (Fig. 3A and Supplemental Movies 1
and 2). This loss of fluorescence occurs within a single interval
between successive frames (i.e., 30 s) and is not accompa-
nied by a loss of the cell corpse, which is seen to persist on
accompanying DIC images (Fig. 3B). Loss of GFP is never seen
in cells that have normal morphology or are moving or ex-
tending pseudopodia, suggesting that it is specific to the pro-
cess of apoptosis in these cells.
Biochemical confirmation of neutrophil apoptosis
To confirm these morphological changes do indeed represent
neutrophil apoptosis, identification of GFP-positive cells exhib-
iting biochemical markers of apoptosis would be required. As
GFP within apoptotic neutrophils ceases to fluoresce following
Figure 2. Pharmacological acceleration of neutrophil apoptosis is accompanied by a reduction in neutrophil number at the inflammatory site.
Three dpf zebrafish larvae were subjected to tail transection under anesthetic, as described in Materials and Methods. (A) Pyocyanin (Pyo), a
phenazine pigment exotoxin of P. aeruginosa (50 M, a kind gift of Graham Taylor, University College London, UK; purified as described previ-
ously [20]), was added at 4 h after injury and counts of neutrophil number made after a further 4 h. The effect of pyocyanin on reducing neutro-
phil number was blocked by zVD.fmk, a pan-caspase inhibitor (100 M). *, P  0.05, for control versus pyocyanin; not significant for control ver-
sus other columns, one-way ANOVA with Dunnett’s post-test correction; n  at least 16, performed as three independent experiments. (B) Rosco-
vitine, an inhibitor of CDK (20 M), DMSO, or pyocyanin (50 M) was added 4 h following tailfin transection. After a further 20 h (at 20°C,
approximately equivalent to 12 h at 28°C), following addition of the compounds, neutrophil number was assessed by manual counting. Pyocyanin
and roscovitine reduce neutrophil number at this time-point. For the comparisons indicated by capped lines, * denotes a P value of 0.05, ascer-
tained by one-way ANOVA with Dunnett’s post-test correction; n  at least 24, performed as three independent experiments. (C) Flumethasone at
the dose shown, DMSO (negative control), or pyocyanin (50 M, positive control) was added at 4 h following tailfin transection as above. After a
further 20 h (at 20°C, approximately equivalent to 12 h at 28°C) following addition of the compounds, neutrophil number was assessed by manual
counting. **, P  0.01, ascertained by one-way ANOVA with Dunnett’s post-test correction.
Figure 3. Morphological features of apoptosis are seen dur-
ing time-lapse analysis of neutrophilic inflammation in ze-
brafish. (A) Four hours following transection of the tailfin
under Tricaine anesthesia, a 4-dpf zebrafish larva was re-
anesthetized and mounted in 1% low melting-point agarose
containing 0.02% Tricaine. During this time-lapse series
(showing a single confocal slice), a neutrophil is seen to
cease movement and assume a rounded shape. This is fol-
lowed by loss of GFP fluorescence. Times since initiation of
time-lapse are shown (h:m:s.ms). The images have been selected to be representative of the series, which can be seen in full in Supplemental Mov-
ies 1 and 2. Photomicrographs were taken with a 40 Plan NeoFluar oil immersion objective, NA1.3 (Zeiss). As a result of the thickness of the
tissue section here, the individual cells are not visible on DIC images. Exposure times were minimized, and there was no evidence of any adverse
effects over 16 h of imaging. Similar events are seen under wide-field time-lapse microscopy. (B and C) A similar event occurring in the tailfin en-
ables imaging under DIC of the persisting neutrophil cell “corpse.” (B) A fluorescent neutrophil showing features of apoptotic morphology in the
tailfin during inflammation resolution. (C) The same neutrophil, a single frame (30 s) later, showing that the neutrophil corpse persists, and the
GFP signal has been lost completely.
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the morphological changes of apoptosis, a second marker of
neutrophil lineage was used. It is known that following apopto-
sis of mammalian neutrophils in tissue culture, endogenous
MPO activity persists, and apoptotic neutrophils can be visual-
ized by histochemical peroxidase stains [26]. Therefore, to
confirm biochemically that neutrophil apoptosis was occurring,
fluorogenic peroxidase substrates (TSA) were used to stain for
mpx activity in wild-type fish, fixed at 12 h after injury [25].
TSA-stained larvae were then stained for apoptosis-specific
DNA cleavage by TUNEL. In these fish, double-positive cells
(positive for neutrophil and apoptosis markers) were observed
always to have the typical rounded morphology of apoptotic
cells (Fig. 4, A and B). It should be noted that this occurs in-
dependently of transgene expression and in vivo fluorescence
imaging. The mean number  sem of dual-positive cells seen
(at the site of injury) per fish was 3.0  0.6 (n8). Total
mean  sem number of neutrophils at this site is 67.8  6.2.
Thus, at this time-point, 4.4% of detectable neutrophils are
apoptotic. This is consistent with numbers seen in mammalian
models and disease states [27, 28] and is likely to be a contrib-
utor to inflammation resolution in this model.
These experiments were repeated using the Tg(mpx:
GFP)i114 line, using TUNEL staining to mark apoptosis and
an anti-GFP antibody to mark neutrophils. The number of
neutrophils and rates of change of neutrophil number were
comparable in the transgenic line and wild-type lines (data
not shown). However, there was a dramatic reduction in the
number of dual-positive cells seen using this technique. The
mean number of apoptotic neutrophils observed in the
Tg(mpx:GFP)i114 fish was 0.2  0.2 (approximately one for
every five fish examined; P0.02 compared with numbers
seen with FITC-TSA histochemical mpx staining). An exam-
ple of apoptotic neutrophils in a larva stained with anti-GFP
antibody is shown in Figure 4B and Supplemental Movie 3.
Modulation of rates of apoptosis by inflammatory
modulators
To confirm that some of the alterations in rates of inflamma-
tion resolution seen above were a result of alterations in rates
of apoptosis, we tested a number of compounds for their abil-
ity to suppress apoptosis of neutrophils during inflammation
resolution in vivo. Zebrafish larvae at 10 dpf were anesthetized
and subjected to tailfin transection as above and the number
of apoptotic neutrophils at 12 h postinjury assessed by count-
ing of dual (FITC-TSA/rhodamine TUNEL)-positive cells (Fig.
4C). All compounds tested significantly suppressed levels of
apoptosis, suggesting that at least part of their action is via a
specific delay of neutrophil apoptosis.
Macrophage uptake of apoptotic neutrophils
The low numbers of visible apoptotic neutrophils seen in this
and other models of resolving inflammation might be a result
of rapid recognition and uptake of apoptotic neutrophils by
macrophages [26]. This is necessary, as apoptosis without up-
take of the apoptotic corpse permits secondary necrosis to oc-
cur, with release of the histotoxic granule contents of the neu-
trophils. A proportion of the macrophages entering the site of
Figure 4. Dual staining for neutrophil-specific mpx and
DNA nick-ends (TUNEL) provides biochemical confirma-
tion of neutrophil apoptosis during resolution of neutro-
philic inflammation in unmanipulated zebrafish embryos.
Seven dpf zebrafish were injured and fixed 12 h later in
4% paraformaldehyde at 4°C. Neutrophils were revealed by (A) FITC-TSA staining (wild-type fish) for peroxidase activity or (B) immunostaining
for GFP (mpx:GFP fish), in combination with TUNEL staining with the ApopTag Red kit. Dual-positive cells representing apoptotic neutro-
phils can be seen in the right panel of A and B. The images shown are maximum-intensity projected images of at least 20 sections in the Z
dimension. Images were taken using a 60 Plan Apo Oil immersion NA1.40 (Olympus). Colocalization of fluorescence in single sections can
be seen in Supplemental Movie 3. (C) Larvae at 10 dpf were injured as described previously and treated with the compounds indicated. At
12 h after injury, larvae were fixed and stained for colocalization of neutrophil (FITC-TSA) and apoptotic (TUNEL) markers as above. Dual-
positive cells and total neutrophil count were scored from confocal images. Data shown are percent neutrophils costaining with TUNEL
markers (i.e., apoptotic neutrophils). P  0.05 for all treatments compared with DMSO control by one-way ANOVA with Dunnett’s post-test
correction. zVAD.fmk, zVD.fmk.
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inflammation in the zebrafish tail-wounding assay can be visu-
alized by staining with neutral red, a vital dye taken up by
macrophages by lipid pinocytosis [5]. When macrophages
are stained in this way at a variety of time-points in mpx:
GFP transgenic larvae, the time course of macrophage and
neutrophil migration to an injury site can be observed (Fig.
3A). The peak number of neutral red-positive macrophages
follows the peak number of neutrophils by 4 – 6 h, and these
macrophages persist at the inflammatory site, beyond the
time when neutrophilic inflammation has resolved.
To demonstrate the remains of ingested neutrophils within
macrophages, zebrafish phagocytes were stained by L-plastin
immunofluorescence [29] and the presence of mpx identified
using Cy3-TSA staining. Two populations of myeloid cells
could be distinguished: neutrophils were L-plastin-positive/
Cy3-TSA-positive, and macrophages were L-plastin-positive/
Cy3-TSA-negative. In uninjured fish, no Cy3-TSA-positive mate-
rial was seen within macrophages. However, at 12 h postinjury
in 7 dpf fish, macrophages containing small, localized foci of
Cy-3-TSA-positive neutrophil material could be identified
clearly. This material was always seen as small circular bodies
within the macrophages, consistent with macrophage ingestion
of apoptotic neutrophils (Fig. 5, B and C, and Supplemental
Movies 4 and 5). In a further experiment, using triple staining
for neutrophilic material (Cy5-TSA), apoptotic markers (rho-
damine TUNEL), and leukocyte markers (L-plastin immuno-
histochemistry), it was possible to identify rare examples of
macrophages containing triple-positive, small rounded inclu-
sions, consistent with ingestion of apoptotic neutrophil mate-
rial (Fig. 5D). This is consistent with a functional role for neu-
trophil apoptosis and macrophage clearance in the resolution
of inflammation in this model.
DISCUSSION
We have identified a range of pharmacological agents that
modulate the outcome of experimentally induced inflamma-
tion in an in vivo model of spontaneously resolving inflamma-
tion. These agents also modulate neutrophil apoptosis in
mammalian systems. We have also shown that apoptotic neu-
trophils can be identified during inflammation resolution in
this model at levels consistent with a role in inflammation res-
olution. The relative contribution of apoptosis and other
forms of inflammation resolution, such as retrograde chemo-
taxis, has not been explicitly investigated.
Figure 5. Macrophages take up apoptotic neutrophils during inflammation resolution in vivo. (A) Three dpf mpx:GFP zebrafish were injured as
described previously. Two hours before the time indicated, larvae were stained with neutral red for 2 h. The number of neutral red-positive mac-
rophages and GFP-positive neutrophils was counted for each fish under bright-field illumination and 488 nm fluorescent illumination, respectively.
(B and C) Seven dpf wild-type zebrafish were injured and fixed 12 h later in 4% paraformaldehyde at 4°C, followed by staining for mpx activity
and L-plastin immunohistochemistry, as described in Materials and Methods. Single macrophages can be seen containing TSA-positive neutro-
philic material. (C) A neutrophil is shown alongside for comparison. (D) Cy5-TSA staining (purple) was combined with L-plastin staining (green)
and TUNEL staining (red) to show colocalization of apoptotic markers and neutrophil markers within a macrophage. Three-dimensional recon-
structions are shown in Supplemental Movies 4 and 5 to confirm location of the Cy-3 TSA-positive material completely within the macrophage.
Images were taken using a 60 Plan Apo Oil immersion NA1.40 (Olympus).
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The pharmacological agents used in these studies were cho-
sen because of their ability to delay apoptosis of human neu-
trophils in vitro. The actions of these groups of agents on neu-
trophil apoptosis are unrelated in the mechanism. It therefore
seems unlikely that they are all having their effects via pro-
cesses other than apoptosis. Moreover, although rates of de-
tectable neutrophil apoptosis are low, agents that suppress
apoptosis of neutrophils in vitro, including caspase inhibitors
and inflammatory regulators such as LPS, also suppress them
in this in vivo model.
The most potent inhibitor of inflammation resolution tested
was zVD.fmk [9]. By comparison, the effects of other caspase
inhibitors were relatively weak and only readily apparent when
resolution was considered within individual fish. This may sim-
ply reflect the larger size and hence, poorer tissue penetration
of the tetrapeptide inhibitors. Alternatively, the main target of
zVD.fmk may be a caspase with different substrate specificities,
either a different member of the caspase family or one of the
caspases tested, but with different substrate preferences in ze-
brafish. However, there appears to be a high degree of homol-
ogy in substrate specificities between mammalian and zebrafish
caspases [30]. The doses of caspase inhibitors used in this
study are high, and this will reduce the specificity of the
caspase inhibitors used; thus, care should be taken when inter-
preting these results. However, the doses used are similar to
those used in many experiments on human neutrophils (re-
viewed in ref. [31]).
The phenazine pigment pyocyanin, produced by P. aerugi-
nosa, has been shown to induce apoptosis of neutrophils puri-
fied from human peripheral blood [20] and in the lungs of
mice with experimental Pseudomonas pneumonia [21]. We now
show that it is also able to reduce numbers of neutrophils dur-
ing zebrafish-tailfin injury-induced inflammation in a caspase-
dependent manner, further highlighting the similarities be-
tween this model and mammalian models of neutrophilic in-
flammation. Similarly, roscovitine is able to accelerate
inflammation resolution in this model, as it is in mammalian
models [2]. These compounds were used as positive controls
to establish a compound-screening paradigm to assess this
model for its role as a vehicle for anti-inflammatory drug dis-
covery. Of the 12 compounds identified, six have known anti-
inflammatory activity and include the corticosteroid flumetha-
sone. Perhaps surprisingly in this context, corticosteroid treat-
ment has been shown to delay the apoptosis of isolated human
neutrophils [32, 33]. However, in an in vivo setting, it may
well be that effects on neutrophil apoptosis are balanced by
effects on other cell types, for example, reduction in inflam-
matory mediators by tissue cells adjacent to the site of injury.
Following an inflammatory insult, neutrophils move through
tissues, up local gradients of chemotactic factors to provide
defense against pathogenic organisms, and take up tissue de-
bris. Tissue neutrophils subsequently meet one of three possi-
ble fates: they may be lost from the tissues into inflammatory
exudates (e.g., into the airways [34], onto the dermis [35], or
into other compartments, such as the pleura [36] or synovial
space [37]); they may migrate away from the site of inflamma-
tion [24, 38–41]; or they may undergo apoptosis in situ and
be taken up by macrophages, which subsequently undergo re-
verse chemotaxis [42]. Failure of these processes may lead to
persisting inflammation and tissue damage. These disposal
routes are not mutually exclusive, and the balance of the three
routes may differ in different tissues in response to different
stimuli and at different times. Of the three processes, in vivo
evidence that neutrophil apoptosis is functional in the resolu-
tion of tissue neutrophilia has been hardest to obtain. Evi-
dence for the in vivo importance of neutrophil apoptosis
comes from visualization of apoptotic neutrophils in tissue ex-
udates or in fixed tissue samples from a range of experimental
and clinical scenarios. For example, apoptotic neutrophils
have been demonstrated in lung lavage from patients with
acute respiratory distress syndrome [28], in joint fluid of pa-
tients with rheumatoid arthritis [26, 37], and in pleural fluid
in experimentally induced pleurisy [43]. In addition, it is pos-
sible to identify apoptotic neutrophils by histological examina-
tion of fixed samples taken from resolving inflammation in
vivo [44]. Manipulation of neutrophil apoptosis has been
shown to modulate inflammation resolution in experimentally
induced pleurisy [2, 43], in bleomycin-induced lung injury,
and serum-induced arthritis [2]. In all of these models, num-
bers of identifiable apoptotic neutrophils are low but are func-
tionally important. The ability to visualize apoptosis of neutro-
phils as it occurs using tissue-specific apoptosis reporter trans-
genics and to observe the effects of pharmacological and
genetic manipulations on neutrophil apoptosis in living tissues
would be important additions to this field.
The data presented here show that neutrophil apoptosis
contributes to the spontaneous resolution of inflammation in
a zebrafish model of neutrophilic inflammation. Morphologi-
cal and biochemical features of neutrophil apoptosis have
been described, along with evidence of the functional conse-
quence of neutrophil apoptosis in vivo (macrophage uptake).
Moreover, targeted pharmacological modulation of neutrophil
apoptosis leads to changes in amount of spontaneous inflam-
mation resolution. This is in keeping with data demonstrating
apoptotic neutrophils at sites of resolving inflammation in ani-
mal models of disease and human disease states [26, 28, 37].
The numbers of apoptotic neutrophils are low in this study
but consistent with the percentage of apoptotic cells seen in
other models [10, 27, 28]. These low levels of apoptosis can be
suppressed further by caspase inhibitors, LPS, and dbcAMP,
demonstrating that modulation of neutrophil apoptosis may
explain, at least part, the action of these compounds on in-
flammation resolution. A unique aspect of this model is the
ability to visualize the cellular events comprising the apoptotic
program, as they occur in tissue neutrophils participating in
the inflammatory response. Other models permit the analysis
of neutrophils removed from inflammatory sites (albeit usually
from exudates rather than from the tissues per se) or the post-
fixation analysis of apoptosis. However, the direct visualization
of the apoptotic program in vivo would appear to be a distinct
possibility in this model, potentially giving a unique window
into the resolution of neutrophilic inflammation.
The difficulty in identifying individual apoptotic neutrophils
is compounded by the observed loss of GFP fluorescence as
neutrophils undergo apoptosis. This loss of fluorescence was
unexpected and may be cell type-specific. We have not ob-
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served this phenomenon in a range of other tissue-culture cell
types, in which GFP derivatives have been used to aid assess-
ment of apoptosis [45, 46]. However, the loss of fluorescence
in this context might explain the difficulty in identification of
apoptotic neutrophils by other groups who have studied GFP
neutrophils in vivo. The mechanism for the loss of fluores-
cence is not clear, although potential explanations include the
quenching of fluorescence by hypochlorous acid [47] or diges-
tion of GFP by granule proteases within the neutrophil. One
explanation for the differences in number of TUNEL-positive
neutrophils, when identified by anti-GFP antibody compared
with histochemical staining, is loss of the GFP epitope during
apoptosis. Definitive experiments to prove this will require
generation of larvae deficient in mpx and granule proteases.
Work by other groups [24] has identified retrograde chemo-
taxis as a mechanism by which zebrafish inflammation may
resolve, and there is evidence that a similar process occurs in
certain human disease states [38]. Retrograde chemotaxis may
coexist with neutrophil apoptosis as a mode of resolution of
inflammation, and there may be circumstances in which one
form of clearance may predominate. The exact balance of
these two processes for each inflammatory scenario remains to
be determined, and a complete analysis would also require
quantitation of ongoing neutrophil recruitment. It seems likely
that the balance of new neutrophil recruitment, retrograde
chemotaxis, and clearance by apoptosis will be different for
different inflammatory stimuli (including differing wound sizes
and the presence or absence of pathogens), even within the
zebrafish tailfin wound model. This would also be consistent
with the observation that neutrophil apoptosis has not been
observed in smaller wounds in comparison with the more ex-
tensive wounds used in these studies [24, 40]. The loss of GFP
fluorescence during neutrophil apoptosis would mean that
specific dual staining would be required, and observation
alone would be insufficient. In addition, the use of older ze-
brafish (7–10 dpf) was necessary for us to identify conclusively
apoptotic neutrophils, likely to be as a consequence of the in-
creased numbers of neutrophils required to detect this tran-
siently detectable in vivo event. In contrast, the numbers of
neutrophils recruited to the smaller wounds of Day 3 or 4 lar-
vae in other studies would be unlikely to result in detectable
numbers of apoptotic cells. For example, Mathias et al. [24]
and Brown et al. [40] show peak numbers of neutrophils of
10/fish, compared with the figure of almost 70/fish in these
experiments. With rates of detectable apoptosis of 4.4%, they
would be unlikely to be able to detect apoptotic cells, even
had they stained specifically for them. The specificity of this
particular transgenic zebrafish line makes it an ideal model for
the future studies to determine the relative contributions of
apoptosis and retrograde chemotaxis in the resolution of neu-
trophilic inflammation.
This study confirms neutrophil apoptosis occurs in tissues
during inflammation resolution and is amenable to pharmaco-
logical manipulation. The unique features of zebrafish make
them a powerful tool to study the in vivo fate of inflammatory
cells following genetic or pharmacological perturbation of the
apoptosis pathways. The advantages of this model will be ex-
ploited in forward genetic and “chemical genetic” screens to
gain an understanding of the controls of neutrophil apoptosis
and identify compounds with the potential to hasten resolu-
tion of tissue neutrophilia in inflammatory disease.
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